Condition stack · 7 min read

Kidney stone prevention — what the controlled trials actually support

Updated 2026-05-27 · Reviewed by SupplementScore editors · No sponsorships

Roughly 50% of first-time stone formers will have a second stone within 5–10 years if nothing changes. The American Urological Association and European Association of Urology guidelines converge on a small, well-evidenced toolkit: aggressive hydration, dietary calcium normalisation (counter-intuitively — low-calcium diets raise stone risk), potassium citrate for documented hypocitraturia, and stone-type-specific tailoring. Most "stone prevention" supplements sold to consumers are not in the guidelines and don't have the trial evidence behind them. The single highest-yield intervention is fluid intake.

Important. Recurrent kidney stones warrant a 24-hour urine collection and stone-composition analysis — not generic supplement strategies. Treatment is meaningfully different for calcium oxalate vs uric acid vs cystine vs struvite stones. This page is a complement to, not a replacement for, urology follow-up.

The trial-supported stack

Layer 1 · Hydration baseline

Water — the single most important intervention

Dose: enough to produce ≥2.5 L of urine per 24 hours (typically 3.0–3.5 L of fluid intake, depending on losses and diet).

Borghi's 5-year RCT (PMID 8648464) randomised first-time stone formers to high-fluid intake vs control; the high-fluid group had a 12% recurrence rate vs 27% in controls. Dilution lowers supersaturation of every stone-forming species — this is mechanism-agnostic and works for nearly all stone types. The dose-response is real and most consumers under-drink at baseline.

Layer 2 · Calcium oxalate stones

Potassium citrate

Dose (prescription): 40–60 mEq/day in divided doses, titrated to urine pH 6.5–7.0 and citrate ≥500 mg/24h. OTC potassium citrate exists at lower doses but the trial evidence is on prescription dosing.

Multiple RCTs (Barcelo 1993, Ettinger 1997, Soygür 2002) and meta-analyses show meaningful reductions in calcium oxalate recurrence in hypocitraturic patients. Alkalinising the urine inhibits crystal nucleation and binds free calcium. The guideline-cited form is prescription potassium citrate, not "lemon water" — which contains far less citrate than the trial doses.

Layer 3 · Magnesium as an adjunct

Magnesium citrate or oxide

Dose: 400–600 mg elemental magnesium/day, split AM and PM, with food.

Magnesium binds oxalate in the gut, reducing absorbable load, and is a co-inhibitor of calcium oxalate crystal nucleation. Trial evidence is weaker than for potassium citrate but several small studies (Johansson 1980, Ettinger 1988) support modest recurrence reductions when added to a citrate regimen. Citrate and oxide forms have both been used; glycinate is fine but unstudied for this endpoint.

Layer 4 · Uric acid stones

Urine alkalinisation (potassium citrate or bicarbonate)

Dose: titrate to urine pH ≥6.5 (uric acid solubility rises sharply above this threshold). Often combined with allopurinol in hyperuricosuric patients.

Uric acid stones are uniquely treatable by alkalinisation — at urine pH ≥6.5, existing stones can actually dissolve. This is the rationale for the alkalinising-citrate approach. Pure uric acid stones are radiolucent on plain film and may be missed; CT and stone-composition analysis are essential.

Layer 5 · Dietary calcium (NOT a supplement)

Adequate dietary calcium intake

Target: 1000–1200 mg/day from food, taken with oxalate-containing meals.

The counter-intuitive finding from the Curhan / Nurses' Health and Health Professionals cohorts: low dietary calcium intake increases calcium oxalate stone risk, because unbound dietary oxalate is absorbed more efficiently. Calcium taken with oxalate-rich foods binds oxalate in the gut. Calcium supplements taken separately from meals do not have the same protective effect and may modestly raise risk — this is a key distinction patients miss.

Layer 6 · Dietary modulation

Sodium and animal protein reduction

Targets: sodium <2300 mg/day; animal protein moderate (≤0.8 g/kg/day for high-risk patients).

High dietary sodium raises urinary calcium excretion. High animal protein raises uric acid and lowers citrate. The DASH-style pattern (high in fruits, vegetables, low-fat dairy; moderate in animal protein) is associated with lower stone risk in observational data. These are lifestyle, not supplement, interventions — but they materially change supplement effectiveness.

What to skip

What works for whom

The single most important step for any recurrent stone former is stone-type analysis. The "right" stack is meaningfully different for calcium oxalate (the majority — citrate + hydration + dietary calcium + magnesium), calcium phosphate (hydration + dietary modulation; citrate is less helpful and can paradoxically worsen calcium phosphate stones at high urine pH), uric acid (alkalinisation is curative for existing stones), cystine (high fluid intake target ≥4 L/day plus often tiopronin or D-penicillamine — specialist territory), and struvite (infection-driven; antibiotics and surgical clearance, not supplement-managed).

A 24-hour urine collection identifies the metabolic drivers — hypercalciuria, hypocitraturia, hyperoxaluria, hyperuricosuria — and lets the urologist target interventions. Generic supplement strategies without this work-up are guessing.

Sources

Related supplements

Related conditions